World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
65
Citations
18285
World Ranking
2817
National Ranking
1332

Peter Kufer publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Peter Kufer sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 191 publications — 31st percentile

31% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Peter Kufer D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Peter Kufer sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 65 D-Index — 43rd percentile

43% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Peter Kufer is affiliated with Amgen in the United States and works primarily in the field of Medicine, with a focus on Oncology. Their research encompasses several subfields including Radiology, Nuclear Medicine and Imaging, Biomedical Engineering, Immunology, and Pulmonary and Respiratory Medicine.

Their work centers on key topics such as CAR-T cell therapy research, Cancer Immunotherapy and Biomarkers, Monoclonal and Polyclonal Antibodies Research, Immunotherapy and Immune Responses, Radiopharmaceutical Chemistry and Applications, Nanowire Synthesis and Applications, and Nanofabrication and Lithography Techniques.

Among their frequent co-authors are Sabine Stienen, Gerhard Zugmaier, Maria-Elisabeth Goebeler, Ralf C. Bargou, and Joachim Wahl.

Peter Kufer has published in several notable journals including Cancer, Cancer Research, Immunotherapy, Clinical Cancer Research, and the Journal of Clinical Oncology.

  • "The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types," 2020, Cancer
  • "Pasotuxizumab, a Bite ® Immune Therapy for Castration-Resistant Prostate Cancer: Phase I, Dose-Escalation Study Findings," 2020, Immunotherapy
  • "The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer," 2021, Clinical Cancer Research
  • "Phase I study of pasotuxizumab (AMG 212/BAY 2010112), a PSMA-targeting BiTE (Bispecific T-cell Engager) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)," 2020, Journal of Clinical Oncology
  • "Abstract ND06: AMG 305, a dual targeting BiTE®molecule with selective activity for solid tumors that co-express CDH3 and MSLN," 2023, Cancer Research

Best Publications

  • Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody

    Ralf Bargou;Eugen Leo;Gerhard Zugmaier;Matthias Klinger

  • Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

    Max S. Topp;Peter Kufer;Nicola Gökbuget;Mariele Goebeler

  • A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity

    Matthias Mack;Gert Riethmuller;Peter Kufer

  • A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.

    Anja Löffler;Peter Kufer;Peter Kufer;Peter Kufer;Ralf Lutterbüse;Ralf Lutterbüse;Ralf Lutterbüse;Florian Zettl;Florian Zettl;Florian Zettl

  • Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.

    Matthias Klinger;Christian Brandl;Gerhard Zugmaier;Youssef Hijazi

  • Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

    Max S. Topp;Nicola Gökbuget;Gerhard Zugmaier;Evelyn Degenhard

  • Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody

    Torsten Dreier;Grit Lorenczewski;Christian Brandl;Patrick Hoffmann

  • Novel method for the production of anti-human antigen receptors and uses thereof

    Peter Kufer;Tobias Raum

  • Blinatumomab: a historical perspective.

    Dirk Nagorsen;Peter Kufer;Patrick A. Baeuerle;Ralf Bargou

  • Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells.

    Sonja Offner;Robert Hofmeister;Andrea Romaniuk;Peter Kufer

  • Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study

    Maria-Elisabeth Goebeler;Stefan Knop;Andreas Viardot;Peter Kufer

  • BiTEs: bispecific antibody constructs with unique anti-tumor activity.

    Evelyn Wolf;Robert Hofmeister;Peter Kufer;Bernd Schlereth

  • MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors.

    Klaus Brischwein;Bernd Schlereth;Benjamin Guller;Carola Steiger

  • CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF

    Bernd Dorken;Gert Riethmuller;Peter Kufer;Ralf Lutterbuse

  • Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow.

    A Zippelius;P Kufer;G Honold;M W Köllermann

  • A revival of bispecific antibodies

    Peter Kufer;Ralf Lutterbüse;Patrick A. Baeuerle

  • Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen

    Claudia Bluemel;Susanne Hausmann;Petra Fluhr;Mirnalini Sriskandarajah

  • T Cell Costimulus-Independent and Very Efficacious Inhibition of Tumor Growth in Mice Bearing Subcutaneous or Leukemic Human B Cell Lymphoma Xenografts by a CD19-/CD3- Bispecific Single-Chain Antibody Construct

    Torsten Dreier;Patrick A. Baeuerle;Iduna Fichtner;Michael Grün

  • T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells

    Ralf Lutterbuese;Tobias Raum;Roman Kischel;Patrick Hoffmann

  • BiTE: Teaching antibodies to engage T-cells for cancer therapy.

    Patrick A Baeuerle;Peter Kufer;Ralf Bargou

Frequent Co-Authors

Patrick A. Baeuerle
Patrick A. Baeuerle Cullinan Oncology, Inc.
Gert Riethmüller
Gert Riethmüller Ludwig-Maximilians-Universität München
Hermann Einsele
Hermann Einsele University of Würzburg
Wolfgang Hiddemann
Wolfgang Hiddemann Ludwig-Maximilians-Universität München
Andreas Wolf
Andreas Wolf Max Planck Society
Peter A. Kiener
Peter A. Kiener AstraZeneca (United Kingdom)
Andreas Mackensen
Andreas Mackensen University of Erlangen-Nuremberg
Oliver G. Ottmann
Oliver G. Ottmann Cardiff University
Dieter Hoelzer
Dieter Hoelzer Goethe University Frankfurt
Bernd Dörken
Bernd Dörken Charité - University Medicine Berlin

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in advancing their career in immunology, pursuing related healthcare degrees online can be a strategic move. Many professionals in this field explore nursing pathways that complement their scientific expertise. An accelerated nurse practitioner program offers a fast-tracked route to becoming a nurse practitioner, providing essential clinical skills and advanced knowledge for patient care.

Transitioning within nursing specialties is also common. For example, acute care certification for FNP (Family Nurse Practitioner) holders enables them to focus on critical care settings, broadening their scope and job opportunities in healthcare environments requiring specialized skills.

Additionally, those new to healthcare can enroll in online accelerated nursing programs for non nurses. These programs help individuals without a nursing background enter the field efficiently while gaining the necessary credentials.

Salary considerations are important when selecting a degree path. Exploring the average doctorate in nursing salary by state can help candidates understand earning potentials across different locations, guiding informed decisions about education and career development.

By leveraging these online degree options and certifications, students can build versatile skill sets that intersect with immunology, enhancing their contributions to healthcare and research.

Learn more about these pathways through the following resources:

Best Scientists Citing Peter Kufer

Trending Scientists